Phase 3
Completed N=14
Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers
Healthy
Source: ClinicalTrials.gov NCT01253824 ↗
Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Jun 2014
Primary outcomePrimary: Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA)) — 1654.7; 2478.0; 1872.6; 2434.9 pg・day/mL,
Summary
The purpose of this study is to compare the serum levels of estradiol, progesterone, FSH and LH in NPC-01 or IKH-01 one treatment cycle with those in before and after administration cycle.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA)) |
1654.7; 2478.0; 1872.6; 2434.9 | — |
| PRIMARY Comparing Progesterone AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA)) |
54.171; 93.148; 89.711; 59.344 | — |
| SECONDARY Comparing FSH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA)) |
-9.609; -4.380; -4.404; 0.538 | — |
| SECONDARY Comparing LH AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA), Follow up(FU)-Study Drug Administration(ADA)) |
60.874; 57.124; 61.571; 59.837 | — |
Eligibility Criteria
Inclusion Criteria
- Healthy female aged between 20 to 35 years
- BMI:18.0-26.0
Exclusion Criteria
- Females who are pregnant
- Drug use affecting sex hormone secretion
Data sourced from ClinicalTrials.gov (NCT01253824). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.